First Patient Enrolled for Phase III Clinical Trial of Zhaoke Ophthalmology’s wet Age-related Macular Degeneration (wAMD) Drug, TAB014

Zhaoke Ophthalmology’s NDA for Cyclosporine A (CsA) Ophthalmic Gel for the Treatment of Dry Eye Disease is Accepted for Review by the CDE

First Patient Enrolled for Zhaoke Ophthalmology’s Myopia Progression Control Drug NVK002 Phase III Bridging Clinical Trial (Mini-CHAMP) in China

Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia

Zhaoke Ophthalmology Presented the Results of the Phase III Clinical Trial (COSMO) of CsA Ophthalmic Gel at ARVO 2022 Annual Meeting